KR950703345A - COMPOSITION BASED ON POLYOXYETHYLENE-POLYOXYPROPYLENE BLOCK COPOLYMERS AND CONTAINER CONTANING IT - Google Patents

COMPOSITION BASED ON POLYOXYETHYLENE-POLYOXYPROPYLENE BLOCK COPOLYMERS AND CONTAINER CONTANING IT Download PDF

Info

Publication number
KR950703345A
KR950703345A KR1019950701458A KR19950701458A KR950703345A KR 950703345 A KR950703345 A KR 950703345A KR 1019950701458 A KR1019950701458 A KR 1019950701458A KR 19950701458 A KR19950701458 A KR 19950701458A KR 950703345 A KR950703345 A KR 950703345A
Authority
KR
South Korea
Prior art keywords
container
solution
daltons
molecular weight
less
Prior art date
Application number
KR1019950701458A
Other languages
Korean (ko)
Inventor
매리 소우
크레이그 윌리암 데이비스
앨리슨 그린 플로이드
Original Assignee
엘. 디. 젠킨스
더 웰컴 파운데이션 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엘. 디. 젠킨스, 더 웰컴 파운데이션 리미티드 filed Critical 엘. 디. 젠킨스
Publication of KR950703345A publication Critical patent/KR950703345A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Packages (AREA)

Abstract

본 발명은 진공 또는 불활성 대기중에 폴리옥시프로필렌/폴리옥시에틸렌의 블록 공중합체의 멸균 주사 용액을 포함하는 약학적으로 허용 가능한 봉인된 컨테이너에 관한 것이며, 상기 용액은 산화 방지제를 실질적으로 함유하지 않으며, pH 5.5 내지 6.5로 완충 처리되어있다.The present invention relates to a pharmaceutically acceptable sealed container comprising a sterile injectable solution of a block copolymer of polyoxypropylene / polyoxyethylene in a vacuum or inert atmosphere, the solution being substantially free of antioxidants, buffered to pH 5.5-6.5.

Description

폴리옥시에틸렌-폴리옥시프로필렌 블록 공중합체가 주성분인 조성물 및 그것을 함유하는 컨테이너(COMPOSITION BASED ON POLYOXYETHYLENE-POLYOXYPROPYLENE BLOCK COPOLYMERS AND CONTAINER CONTANING IT)COMPOSITION BASED ON POLYOXYETHYLENE-POLYOXYPROPYLENE BLOCK COPOLYMERS AND CONTAINER CONTANING IT

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (18)

진공 또는 불활성 대기중에서 하기 일반식(Ⅰ)의 블록 공중합체의 멸균 수성 주사 용액을 포함하는 약학적으로 허용 가능한 봉인된 건테이너;Pharmaceutically acceptable sealed guntainer comprising a sterile aqueous injectable solution of the block copolymer of formula (I) below in a vacuum or inert atmosphere; HO(C2H4O)b(C3H6O)a(C2H4O)bH (Ⅰ)HO (C 2 H 4 O) b (C 3 H 6 O) a (C 2 H 4 O) b H (I) (상기 식에서, a는 (C3H6O)로 나타낸 소수성 부분의 분자량이 950 내지 4000달톤, b는 (C2H4O)로 나타낸 친수성 부분이 공중합체으 50 내지 95중량%를 구성하기 위한 정수이며, 상기 용액은 산화 방지제를 실질적으로 함유하지 않으며, pH가 5.5 내지 6.5 완충 처리되었음)Wherein a is the molecular weight of the hydrophobic moiety represented by (C 3 H 6 O) is 950 to 4000 Daltons, b is the hydrophilic moiety represented by (C 2 H 4 O) is 50 to 95% by weight of the copolymer Integer, wherein the solution is substantially free of antioxidant and has a pH of 5.5 to 6.5 buffered) 제1항에 있어서, 소수성 부분의 분자량이 1200 내지 3500 달톤인 컨테이너.The container of claim 1, wherein the hydrophobic portion has a molecular weight of 1200 to 3500 Daltons. 제1항에 있어서, 소수성 부분의 분자량이 약 1750 달톤이고 블록 공중합체의 총 분자량이 약 8400달톤인 컨테이너.The container of claim 1, wherein the hydrophobic portion has a molecular weight of about 1750 Daltons and the total molecular weight of the block copolymer is about 8400 Daltons. 제1항 내지 제3항 중 어느 한 항에 있어서, 블록 공중합체는 분자량이 15000달톤 이상인 임의의 분자가 실질적으로 없는 컨테이너.The container of claim 1, wherein the block copolymer is substantially free of any molecule having a molecular weight of at least 15000 Daltons. 제4항에 있어서, 분자량이 15k 달톤 보다 큰 분자의 양이 1% 미만인 컨테이너.The container of claim 4, wherein the amount of molecules having a molecular weight greater than 15 k Daltons is less than 1%. 제5항에 있어서, 그 양이 0.5% 미만인 컨테이너.The container of claim 5, wherein the amount is less than 0.5%. 제1항 내지 제6항중 어느 한 항에 있어서, 블록 공중합체의 다중 분산도가 1.4 미만인 컨테이너.The container according to claim 1, wherein the multidispersity of the block copolymer is less than 1.4. 제7항에 있어서, 다중 분산도가 1.3 미만인 컨테이너.8. The container of claim 7, wherein the multiple dispersion is less than 1.3. 제8항에 있어서, 다중 분산도가 1.2 미만인 컨테이너.The container of claim 8, wherein the multiple dispersion is less than 1.2. 제9항에 있어서, 다중 분산도가 1.1 미만인 컨테이너.10. The container of claim 9, wherein the multiple dispersion is less than 1.1. 제1항 내지 제10항중 어느 한 항에 있어서, 블록 공중합체가 용액 1mL당 135 내지 165㎎의 양으로 존재하는 컨테이너.The container according to claim 1, wherein the block copolymer is present in an amount of 135-165 mg per mL of solution. 제11항에 있어서, 양이 용액 1mL당 약 150㎎인 컨테이너.The container of claim 11, wherein the amount is about 150 mg per mL of solution. 제1항 내지 제12항중 어느 한 항에 있어서, pH가 약 6인 컨테이너.The container of claim 1, wherein the pH is about 6. 13. 제1항 내지 제13항중 어느 한 항에 있어서, 용액이 완충제로서 시트레이트를 사용하여 완충 처리된 컨테이너.The container of claim 1, wherein the solution is buffered using citrate as a buffer. 제14항에 있어서, 시트레이트 완충제의 농도가 0.005 내지 0.05M인 컨테이너.The container of claim 14, wherein the concentration of citrate buffer is 0.005 to 0.05M. 제15항에 있어서, 농도가 약 0.01M인 컨테이너.The container of claim 15, wherein the concentration is about 0.01M. 제1항 내지 제16항중 어느 한 항에 있어서, 용액이 인간 혈액 혈청과 실질적으로 등장성인 컨테이너.The container of claim 1, wherein the solution is substantially isotonic with human blood serum. 제1항 내지 제17항중 어느 한 항에 있어서, 불활성 대기가 질소인 컨테이너.The container of claim 1, wherein the inert atmosphere is nitrogen. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019950701458A 1992-10-19 1993-10-18 COMPOSITION BASED ON POLYOXYETHYLENE-POLYOXYPROPYLENE BLOCK COPOLYMERS AND CONTAINER CONTANING IT KR950703345A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929221883A GB9221883D0 (en) 1992-10-19 1992-10-19 Novel formulation
GB9221883.3 1992-10-19
PCT/GB1993/002141 WO1994008596A1 (en) 1992-10-19 1993-10-18 Composition based on polyoxyethylene-polyoxypropylene block copolymers and container containing it

Publications (1)

Publication Number Publication Date
KR950703345A true KR950703345A (en) 1995-09-20

Family

ID=10723654

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950701458A KR950703345A (en) 1992-10-19 1993-10-18 COMPOSITION BASED ON POLYOXYETHYLENE-POLYOXYPROPYLENE BLOCK COPOLYMERS AND CONTAINER CONTANING IT

Country Status (19)

Country Link
EP (1) EP0671919A1 (en)
JP (1) JPH08502284A (en)
KR (1) KR950703345A (en)
AU (1) AU674895B2 (en)
BR (1) BR9307268A (en)
CA (1) CA2147889A1 (en)
CZ (1) CZ63395A3 (en)
GB (1) GB9221883D0 (en)
HU (1) HUT75701A (en)
IL (1) IL107313A0 (en)
MX (1) MX9306467A (en)
NO (1) NO951462L (en)
NZ (1) NZ256890A (en)
PL (1) PL308459A1 (en)
SI (1) SI9300545A (en)
SK (1) SK44795A3 (en)
TW (1) TW276183B (en)
WO (1) WO1994008596A1 (en)
ZA (1) ZA937714B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008287419A1 (en) * 2007-08-10 2009-02-19 Synthrx, Inc. Polymer therapy for the treatment of chronic microvascular diseases
EP3057598A1 (en) 2013-10-16 2016-08-24 Mast Therapeutics, Inc. Diuretic induced alterations of plasma volume
WO2016007542A1 (en) 2014-07-07 2016-01-14 Mast Therapeutics, Inc. Poloxamer therapy for heart failure
US9757411B2 (en) 2014-07-07 2017-09-12 Aires Pharmaceuticals, Inc. Poloxamer therapy for heart failure
WO2016007537A1 (en) 2014-07-07 2016-01-14 Mast Therapeutics, Inc. A poloxamer composition free of long circulating material and methods for production and uses thereof
CN109432511A (en) * 2018-12-29 2019-03-08 常州乐奥医疗科技股份有限公司 A kind of temperature-sensitive hydrogel and its preparation method and application

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3641240A (en) * 1968-09-27 1972-02-08 Wyandotte Chemicals Corp Method for the treatment of an embolus or thrombus
DE3234084A1 (en) * 1982-09-14 1984-03-15 B. Braun Melsungen Ag, 3508 Melsungen PHARMACEUTICAL PREPARATIONS FOR TREATING UNWANTED GROWTHS AND THEIR USE
US4879109A (en) * 1986-05-15 1989-11-07 Emory University Method for treating burns
US4938961A (en) * 1989-04-28 1990-07-03 Geoffrey Collins Organ preservation solution containing pokyethylene gycol and method of performing cardioplegia

Also Published As

Publication number Publication date
AU5284293A (en) 1994-05-09
HUT75701A (en) 1997-05-28
JPH08502284A (en) 1996-03-12
WO1994008596A1 (en) 1994-04-28
SK44795A3 (en) 1996-05-08
TW276183B (en) 1996-05-21
NO951462D0 (en) 1995-04-18
NZ256890A (en) 1995-10-26
IL107313A0 (en) 1994-01-25
AU674895B2 (en) 1997-01-16
GB9221883D0 (en) 1992-12-02
BR9307268A (en) 1999-05-11
NO951462L (en) 1995-06-13
HU9501104D0 (en) 1995-06-28
EP0671919A1 (en) 1995-09-20
MX9306467A (en) 1994-05-31
SI9300545A (en) 1994-06-30
CZ63395A3 (en) 1995-07-12
CA2147889A1 (en) 1994-04-28
PL308459A1 (en) 1995-07-24
ZA937714B (en) 1995-04-18

Similar Documents

Publication Publication Date Title
KR100212346B1 (en) Interferon solution
US4647454A (en) Stable interferon β composition and a method of stabilizing interferon β
FR2369290A1 (en) ADSORBANT FOR PROTEIN
CA2144845A1 (en) Germicidal Detergent-Iodine Compositions Having Reduced Detergent Content
LV12657B (en) Rapamycin composition for intravenous (i / v) administration
KR940001879A (en) Substantially non-irritating oral composition with acceptable taste
KR890007754A (en) Stabilization of Antibodies
ES2123721T3 (en) RAPAMICINE FORMULATIONS FOR INTRAVENOUS INJECTIONS.
KR950703345A (en) COMPOSITION BASED ON POLYOXYETHYLENE-POLYOXYPROPYLENE BLOCK COPOLYMERS AND CONTAINER CONTANING IT
DE69127886D1 (en) Copolymers based on N-alkyl acrylamide, their preparation and their use as thickeners in shampoo compositions
EA199600024A2 (en) Stable liquid composition containing urate oxidase and lyophilized composition for its preparation
AU647933B2 (en) Megestrol acetate formulation
KR890001571A (en) Doxorubicin hydrochloride aqueous solution
KR910005886A (en) Stabilized Leukocyte Interferon
AU2001242328A1 (en) Formulations of active components in the form of a solid dispersion
RU95109876A (en) PACKAGING OF PHARMACEUTICAL PURPOSE
KR910002443A (en) Polyprenyl compound composition for soft capsule
KR910700054A (en) Methods and compositions for the prevention and treatment of hepatitis B virus infection
KR930012023A (en) Stabilized pharmaceutical compositions of the reduced form of aglycosylated recombinant human IL2 and methods for their preparation
RU94042742A (en) Preparation of genetic engineering gamma-interferon
KR920019363A (en) Complex of polyadenylic acid and polyuridic acid
YU65493A (en) NEW BLOCK COPOLYMER PREPARATION
HUT67006A (en) Buffered composition containing mammalian superoxide-dismutase/polyethylene glycol coniugate
RU94017429A (en) Ointment
EP1288185A3 (en) Stabilisation of acrolein

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid